AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic
→ AstraZeneca has picked out its latest computational partner from Toronto, tapping ProteinQure to apply its structure-based design platform for the creation of peptide therapeutic libraries. The pharma giant is responsible for experimental validation of the leads generated from the collaboration.
→ Three months after J&J cast a bright spotlight on Fate’s pioneering stem cell technology, the biotech has secured clearance from the FDA to begin a first-in-human study. The Phase I will test an off-the-shelf CAR-T therapy targeting CD19+ tumors.